lifestyle.celebhomes.net
Home
Sample Page
Author:
Pentixapharm Holding AG
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
May 11, 2026
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism
February 5, 2026
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
January 7, 2026